The White House said Tuesday it is proposing a new rule to expand coverage of anti-obesity and diabetes medications made by companies such as Novo Nordisk (NVO) and Eli Lilly (LLY) for Americans with Medicare and Medicaid.
The new proposal would expand coverage that already includes diabetes and other illnesses, to include obesity, reducing out-of-pocket costs by as much as 95%, the White House said.
"This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation," the White House said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。